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RESEARCH ARTICLE

Open Access

Evaluation of six serological ELISA kits
available in Italy as screening tests for
equine infectious anaemia surveillance
Roberto Nardini1, Gian Luca Autorino1, Charles J. Issel2, R. Frank Cook2, Ida Ricci1, Raffaele Frontoso1,
Francesca Rosone1 and Maria Teresa Scicluna1*

Abstract
Background: ELISAs are known to have a higher diagnostic sensitivity than the agar gel immunodiffusion (AGID)
when employed for serological diagnosis of equine infectious anaemia (EIA). For this purpose, an “in-house” and
five commercial ELISAs available in Italy were assessed by the National Reference Centre for EIA for their analytic
specificity (Sp); precocity, defined as capability of detecting first antibodies produced during a new infection;
precision based on repeatability and reproducibility, estimated from the coefficient of variation (CV); accuracy,
estimated from multiple K and relative Sp and sensitivity (Se). Two serum panels, positive for non-equine
retroviruses and the most frequent equine viruses, were employed to measure analytic Sp. ELISA precocity was also
compared to that of one “in-house” and three commercial AGID kits, employing a panel of sera, collected weekly
from horses infected with modified EIA viruses. Precision and accuracy were defined using results of a panel
containing positive and negative sera examined in an inter-laboratory trial with the participation of the ten Official
Laboratories. Furthermore, a questionnaire was used to assess the appropriateness of each kit for routine use.
Results: Analytic Sp was 100%, while the 75th percentile of CVs for positive sera varied from 0.4% to 12.73% for
repeatability and from 1.6% to 44.87% for reproducibility. Although CV of the negative serum was constantly high,
its outcome was unaltered. Relative Se ranged from 98.2% to 100%, relative Sp was constantly 100% and multiple K
ranged from 0.95 to 1. Precocity differed among the assays: three kits detected 4.8% and 42.9% positive samples on
21 days post infection (dpi), all assays detected positive samples on 28 dpi, between 47.6% and 95.2%. Precocity of
ELISAs was superior to that of the AGIDs except for two assays. In view of the feedback obtained from the
questionnaires, all kits were considered appropriate for routine use.
Conclusion: All ELISAs having high Se and precocity are preferable as a screening test in EIA surveillance
programmes to the AGID tests examined. These two tests can be incorporated in a serial diagnostic pathway to
improve the efficacy of a surveillance plan.
Keywords: Equine infectious anaemia, ELISA, AGID, Comparison, Commercial assays, In-house assays, Surveillance

Background
EIA is a blood-borne disease of equids caused by EIA virus
(EIAV) of the Retroviridae family, subfamily Orthoretrovirinae, genus Lentivirus. EIA has a nearly worldwide distribution and causes sanitary and economic repercussions
on the horse industry. In view of this, it is among the
* Correspondence: teresa.scicluna@izslt.it
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eleven equine diseases listed by the World Organisation
for Animal Health (OIE). In addition, in several countries it is included in national and international Regulations defining the sanitary conditions for horse trade
and movement and is also subjected to regional or national control programmes.
EIAV detection is generally problematical [1, 2],
hence diagnosis of suspect cases and screening during
surveillance programmes are based on antibody detection [3]. At present, for surveillance purposes, the OIE
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considers ELISA as a secondary method to the AGID,
reporting that various factors limit its use. Nevertheless, it is also indicated as suitable for the declaration of
population freedom from disease and for the evaluation
of the efficiency of eradication programmes. The OIE
also recommends that samples positive in ELISA are to
be confirmed using either the AGID or the immunoblot
(IB) [4]. These three methods have been proposed in a
three-tier system that increases the diagnostic efficacy
of EIA [5].
Since 2007, a surveillance programme for the identification and removal of EIA positive animals is on-going
in Italy. In its initial phases, the AGID was employed
both as screening and as confirmatory method respectively by the network of the ten Official Laboratories and
the National Reference Centre (NRC) for EIA. In recent
years, scientific reports [6–8], including those from
Canada [9] and the USA [5], have demonstrated that
ELISA-based tests are potentially more sensitive than
AGID. The NRC adopted a similar approach to that described in these studies to evaluate, on the basis of their
key diagnostic characteristics, the possibility of employing ELISA kits available in Italy for the serological
screening of equid serum samples examined within the
National surveillance programme. The results obtained,
including a comparison with four different AGID kits,
are presented and discussed especially in terms of the
implications of the use of the ELISAs on the efficacy of
the EIA surveillance.

Methods
A summary of the technical characteristics of the ELISAs employed in the present study are presented in
Table 1. One ELISA is an “in-house” assay while the
remaining are commercially produced. Following invitation to participate to the present evaluation, each
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producer kindly provided a kit of the batch that was at
that time available on the market. ELISA #1 [10] and #2
[Scicluna, personal communication, 2016] were the kits
that at the time of the study were already validated according to the OIE guidelines [11]. All the immunoassays were performed according to the manufacturer’s
instructions.
The AGID assays included in the comparison analysis
were performed according to the OIE procedure [4] and
consisted in one in-house and three commercially available AGIDs. Two AGIDs employed a recombinant EIAV
p26 antigen, the third reported the use of a highly purified recombinant viral protein without providing further
information and the remaining kit did not include details
relative to the source of the antigen employed.
The composition and characteristics of the four panels
of sera employed in the evaluation of the ELISAs are described in Table 2 and these will be referred throughout
by an identification number accompanied by a brief
description.
The parameters by which the ELISAs were assessed
are: analytic Sp that was defined employing serum samples containing antibodies to non-equine retroviruses
(Panel 1), along with a set of sera, positive for the most
common equine viral diseases (Panel 2) [12]. Each serum
sample included within these panels was examined in 30
replicates.
Precocity of both ELISA and AGID tests, defined as
the capability to detect the first amounts of antibodies
produced during the onset of an infection, was assessed
using equine serum samples collected at weekly intervals
(day 0 to 28 dpi), from 3 groups of eight horses infected
with one of the following EIAV attenuated strains [10]:
EIAVD9, EIAV Trivalent and EIAVConsensus. Three of the
24 horses, two infected with EIAVConsensus and one with
EIAVD9, seroconverted after 28 dpi (Issel CJ, personal

Table 1 Principal characteristics of the ELISAs employed in the study
ELISA #1

ELISA #2

Type

Competitive

Indirect

Competitive

Competitive

Indirect

Indirect

Antigen

Recombinant p26

Recombinant gag
and env antigens

Purified p26

Recombinant p26

Recombinant
antigennot specified

Recombinant
p26

Run time (‘)

160

135

45

90

20

35

Compared to
ODK+

Compared
to ODK+

Interpretation
Criterion/Formula

Outcome definition

ðODS −ODK Þ
S=P ¼ OD −OD  100
ð Kþ K Þ

ELISA #3

ELISA #4

ðODS −ODK Þ
S=P ¼ OD −OD  100
ð Kþ K Þ

ELISA #5

ELISA #6

PI ¼ 100−

OD S =ODK−  100
PI <30: Neg

S/P ≤ 40: Neg

ODS > ODK+:
Neg

S/P ≤ 50: Neg

ODS < ODK+:
Neg

ODS < ODK+:
Neg

30 ≤ PI ≤ 50:
Equivocal

40 < S/P < 50:
Equivocal

ODS≤ ODK+:
Pos

50 < S/P < 60:
Equivocal

ODS ≥ ODK+:
Pos

ODS ≥ ODK+:
Pos

PI >50: Pos

S/P ≥ 50: Pos

Compared to
ODK+

S/P ≥ 60: Pos

Gag and env: genes of EIAV respectively coding for nucleocapsid and envelope antigens, PI: percentage inhibition, S/P: Corrected Sample /Positive Ratio;
ODS: Optical Density of Sample; ODK-: Optical Density of Negative Control; ODK+: Optical Density of Positive Control; Neg: Negative; Pos: Positive
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Table 2 Characteristics of the panels of sera employed in the study
Panel #

Characteristics

1: Sera positive for non-equine retroviruses

20 sera for feline immunodeficiency virus
20 for feline leukemia virus
20 for enzootic bovine leukosis virus
20 for maedi visna virus

2: Sera positive for other equine viruses

20 sera positive for equine influenza
20 sera positive for equine viral arteritis
20 positive for equine herpes virus −1
20 sera positive for equine herpes virus −4
b,c

3: Sera of 21 horses experimentally infected

84 sera sampled at 0, 14, 21, 28 days post infection (dpi)

4: Interlaboratory test panela

30 sera: 22 positive and 8 negative

a

Available at the EIA National Reference Centre and at the National Reference Centre for Equine Diseases as secondary reference sera
Provided by Gluck Equine Research Center University of Kentucky Lexington, Kentucky
Infected with EIA attenuated virus EIAVD9 EIAVTrivalent, EIAVConsensus (further information is provided in the text)

b
c

communication, 2014), therefore for this study only the
samples of the 21 positive horses were included in
Panel 3.
For the statistical analysis, the Chi Square test was
used to compare the proportions of reactive samples
(positive and equivocal) detected by each method and in
case of a statistical significant difference, the Marascuilo
procedure was employed to investigate for which pair of
assays this occurred. Samples with an equivocal result to
the screening test were reclassified as positive since
these, as for the positively reacting samples, are also forwarded to the NRC for confirmation.
XLStat (Addinsoft®, 2011) was the software utilized for
the statistical analysis and a test obtaining a p value
≤0.05 was considered significant.
The results obtained for panel 4, used in the interlaboratory trial (IT) to which the ten Official Laboratories participated [13], were analysed to assess precision
and accuracy. The panel was examined blindly and consisted of one negative reference serum, included as eight
replicates, and 11 positive samples each provided as two
replicates. The positive samples were prepared from one
positive reference serum diluted with a negative one to
obtain three different reactivity levels that were arbitrarily defined as follows by the NRC, on the basis of the
percentage inhibition (PI) obtained in ELISA #1: strong
positive (SP) with a PI ≥95% (n = 2), medium positive
(MP) with a PI between 75% and 94% (n = 3) and weak
positive (WP) with a PI between 51% and 74% (n = 6).
The positive sera were also confirmed, except for one
WP, in the in-house AGID described above. Both inhouse tests, in use at the NRC, are accredited according
to ISO/IEC 17025 [14].
Precision was assessed using repeatability and reproducibility, which were calculated as follows. Repeatability
was measured using the CV of the results of the two
replicates of each positive serum and of the eight

replicates of the negative obtained in each ELISA run by
every IT participant. The CVs were calculated using the
percentage inhibition (PI) or corrected sample/positive
ratio (S/P) values (see formulae in Table 1). For those assays without an interpretation formula, the results were
normalized according to their set-up, using either the PI
(ELISA #3) or the S/P (ELISA #5 and ELISA #6).
Reproducibility of the assays was evaluated using the
CVs estimated from the gathered results of the IT.
The accuracy of the ELISA kits was defined from the
values obtained for multiple K and relative Sp and Se.
The latter were calculated as the percentage of samples
identified over the total number of expected results, respectively for the negative and positive sera, independently from the different reactivity level. For the reason
mentioned previously, sera with equivocal results were
also here reclassified as positive.
Concordance with the expected results was estimated,
for each laboratory, using K coefficient [15] for those assays (ELISA #3, #5 and #6) with two possible outcomes
(positive and negative) and with a modified K coefficient,
i.e. weighted K [16] for those ELISAs (#1, #2 and #4)
with three expected outcomes: positive, equivocal and
negative, arbitrarily assigning a weight of 0.33 to a partial
concordance. The results of all the laboratories were
then aggregated to calculate the multiple K value [17] of
each assay, which was interpreted as reported in literature [18].
Furthermore, the laboratory personnel participating in
the IT also replied to a questionnaire to investigate the
suitability of the ELISA kits for routine use. This survey
contained 17 questions covering 15 criteria, with preset
answers represented by a scale of 1 (lowest rating) to 5
(highest rating). The questions focused on ease of interpretation of procedures, reagents characteristics, ease
and time of execution, straightforwardness of result formula and result interpretation. Overall rating for each
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question was assigned using the mode obtained from all
the scores reported by the laboratories and summed for
each kit. In addition, the questionnaire also included two
open questions requesting advice and recommendations
for improvements of each kit.

Results
Analytical Sp was 100% for all ELISAs as no crossreactivity was detected for sera of Panel 1 (positive for
non-equine retroviruses) and Panel 2 (positive for common equine diseases). Data on the analytical Se is presented in Fig. 1 and was assessed by the precocity of
antibody detection in the horse sera (Panel 3) collected
at weekly intervals following infection with modified live
viruses. The results of this parameter are expressed as
the percentage of the number of samples detected positive/equivocal out of the total samples expected as positive. Positive samples were detected from 21 dpi, in
ELISA #1 and ELISA#4 identifying each a different positive sample (4.8%) and ELISA #2, identifying 9 positive
samples (42.9%), including the two detected by ELISAs
#1 and #4; on 28 dpi all assays detected a percentage of
positive/equivocal samples, ranging from 47.6% (ELISA
#6) to 100% (ELISA #2).
Positive samples were also detected at 28 dpi by the
different AGID assays with percentages ranging between
28.6% (AGID #4) and 61.9% (AGID #1). In comparing
the precocity of the two different methods, for ELISA #6
this was equal (47.6%) to those of AGIDs #2 and #3 and
for ELISA #4 it was equal (61.9%) to that of AGID #1
(Fig.1).
No statistical differences were observed among the
AGID kits in terms of percentage of positive/equivocal
samples detected. For the ELISAs, differences were detected at 21 dpi with a p value of <0.0001 for the Chi
Square test and with the Marascuilo procedure showing
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a statistical difference between the proportions of positives detected by ELISA #2 with those of ELISAs #3, #5
and #6. Even on 28 dpi, the p value was statistically significant with a value of 0.018 and differences were detected between the proportions of ELISA #2 and ELISAs
#4 and #6.
The distribution of the CV values for repeatability
and reproducibility for each of the assays and for all laboratories are shown in Fig. 2. The 75th percentile of
the CVs of the positive sera did not exceed 12.73% for
repeatability (Fig. 2a) and 44.87% for reproducibility
(Fig. 2b). Conversely, for the negative serum, CVs at the
75th percentile were high with a maximum of 137.54%
for repeatability (Fig. 2c) and 534.31% (Fig. 2d) for reproducibility, without ever modifying the expected
outcome.
The results of the accuracy and total scores obtained
from the questionnaires are reported in Table 3. Relative
Sp was 100% for all the ELISAs while relative Se ranged
from 96.8% (ELISA #5) to 100% (ELISA #6), with all the
remaining kits having a relative Se of >98%. Three laboratories misclassified sixteen sera represented by 1 SP,
2 MP and 13 WP (7 of which corresponded to that
negative in the AGID).
Values of Multiple K ranged from 0.95 (ELISA #3) to 1
(ELISA #6), resulting in an “almost perfect” concordance
according to the adopted classification. Scores for kit
quality perception were very high for all the ELISAs and
varied from 56 (ELISA #1) to 63 (ELISA #4) on a maximum score of 65.
Comments provided by laboratory participants were
reporting as critical the small sample volume used in
ELISA #2, the absence of hazard and safety statements
for kit reagents in ELISAs #3, #4 and #5, the quality of
the reagent containers used in ELISAs #1 and #2, as they
were prone to leaking, and the orientation of the well-

Fig. 1 Percentage of positive and equivocal samples detected by each ELISA and AGID assay for sera sampled at 21, 28 dpi with attenuated EIAV
strains (EIAVD9, EIAVTrivalent and EIAVConsensus)

Nardini et al. BMC Veterinary Research (2017) 13:105
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Fig. 2 Box plot graphs of CVs of repeatability and reproducibility, respectively for positive (a, b) and negative (c, d) sera for each assay. Lower box
represents difference between first quartile and median and upper box difference, between third quartile and median. Y bars represent minimum
and maximum values (due to the graphical representation some values are out of scale). Graph D represents the CVs of the negative serum
considering all laboratories

strips of ELISA #3. In contrast to all other assay formats,
the individual strips of this kit were made up of twelve
wells instead of the more often available format of eight
wells and therefore considered impractical when used in
preset instruments such as automated washers.

Discussion
Results of the present study demonstrated that, except
for precocity, the ELISA kits currently available in Italy
for serological diagnosis of EIA offered similar performance levels. All exhibited high analytical Sp (100%) and
accuracy, with a relative Se between 98.2% and 100%, a
relative Sp of 100% and multiple K values ranging from
0.95 to 1 (see Table 3). Sera misclassification mostly
occurred for the WP (81.3%), with 43.8% of these corresponding to the WP-AGID negative serum. A misclassified sample could be due either to the test sensitivity or
to the laboratory’s technical capability. In particular, the
WP-AGID negative sample was detected as negative by
3 laboratories in one or more of the following ELISAs:
#1, #2, #3, and #5. For the latter two ELISAs, misclassification could be related to their low precocity. Differently
for the other two kits, which demonstrated a high precocity, the use of relatively small serum volumes could
influence their sensitivity, especially when using uncalibrated instrumentation.

All assays were sufficiently repeatable and reproducible
as CV values obtained for the positive sera are similar to
those described in the literature [19–21]. The higher
magnitude of the CVs observed for the negative serum is
due to the low values that this assumes when using the
PI and S/P formulae. In this case, small numerical differences have a greater weight when calculating the CV [9].
Screening tests in a surveillance programme should
detect all levels of true positivity, especially those at borderline level, as a false negative serum would immediately be lost and consequently diminish the efficacy of
the control programme.
Sensitivity, which in this study was also assessed
through precocity, is essential for avoiding the persistence of EIA, not only through the early detection of new
cases that are still mounting their antibody response but
also by the identification of animals with a low serological response [8] that may occur during the chronic
or inapparent phases of AIE and which was evaluated by
the inclusion of WP sera in the IT panel. The best performing kit for precocity was ELISA #2, which could be
ascribed to the use of env gene-derived recombinant
antigen in combination with the p26, employed by all
the other assays [22]. Previous studies report that antibodies against the glycoproteins (transmembrane -gp45
and surface unit -gp90) expressed by the env-gene are
produced earlier than those against the p26 [23–26].

Nardini et al. BMC Veterinary Research (2017) 13:105

Page 6 of 8

Table 3 Values of accuracy, multiple K, and total scores obtained from the questionnaire
ELISA

ReSe (%)

ReSp (%)

Multiple K

Score (maximum score 65)

#1

99.5

100

0.99

56

#2

99.1

100

0.98

57

#3

98.2

100

0.95

59

#4

99.1

100

0.98

63

#5

96.8

100

0.96

58

#6

100

100

1

60

ReSe: relative sensitivity; ReSp: relative specificity

Lacking complete information on the immunological
reagents employed in the ELISAs, this hypothesis requires further investigation, considering also that a
previous study describes that an assay containing just
the gp45 had a lower performance than those using
the p26 [9].
Further investigations are also required to verify the
data obtained for ELISAs #4 and #6, as their precocity
did not exceed that of some of the AGIDs. However, the
performance of these assays relative to the other parameters was perceived as good with relative Sp and Se
values equal to 100% for the first and respectively 99.1%
and 100% for the second, while those of multiple K were
1 for ELISA #4 and 0.98 for ELISA #6. The evaluation of
ELISA kits described here, together with results reported
by other authors [5–9], confirm that most of these testformats have higher or equal levels of overall sensitivity
than the AGID assay, even if this method is still considered as the “Gold Standard” by many governmental
regulatory authorities and is also indicated as an appropriate screening test by the OIE [4]. In addition to the
present data, a limit of detection (LOD) for the AGID of
at least 0.9 Log10 lower than that of the ELISA was
already reported by the same authors [10]. Laboratories
employing this method as screening test are strongly advised to replace it with a more sensitive ELISA to increase the benefits of their control programmes.
The approach presented here for the evaluation of the
performance of the ELISA kits provides the technical
basis for establishing the criteria of choice of a diagnostic assay within the context in which it is be employed.
However, further to the evaluation of the diagnostic parameters that rely on laboratory data, the ease of use of
a kit in the routine is also critical in determining its
choice. For this, questionnaires are valid tools [27, 28]
for considering aspects that are not directly dependant
on the assay’s diagnostic performance, such as the availability and completeness of the validation data, clarity of
the manufacturer’s instructions and practicability of
execution.
The implications of the questionnaire go even beyond
the purpose of this study, as the recommendations provided through these means are also useful to the

manufactures. Worthy of note are the replies provided
in the open questions section, relative to the 5 μl sample
volume analysed by ELISA #2, which was judged as too
small and perceived as a source of variability, even if this
assay was highly performing in all aspects and especially
for precocity. Further to what previously discussed, a
cost benefit analysis should also be included in the decisional process for the choice of a kit, especially in terms
of time of execution in view of the high turnover required in surveillance programmes where a large number of samples are generally examined.
The validation of diagnostic kits, based on the criteria
included in international guidelines, such as those indicated by the OIE [29], provides essential information
for their comparison. Such an approach is adopted in
some countries, as prior to the first release of the diagnostic kits on the market official laboratories either directly validate the kit or verify the technical data
provided by the manufactures. Further to this, every released batch has to be approved by the appointed laboratory through the verification of the performance of
some of the key diagnostic parameters or from the data
presented by the producer.
Validation, according to the international guidelines
for those ELISAs (#3 to #6) which at the time of the
present study was unavailable, would have required a
consistent amount of resources, especially in terms of
time and costs. For this reason, only parameters considered as critical were evaluated for the assessment of the
diagnostic performance of the assays, especially those
that define the kits’ sensitivity, fundamental characteristic for a screening test. The advantage of the simultaneous comparison of the ELISAs kits was that the sera
panels used were the same for all of them, differently
from what would have been the case in an independent
evaluation, therefore increasing the objectivity of the
data produced. In addition, it also gave the opportunity
of using an assessment questionnaire that represents an
innovative method of evaluation. Also, on completion of
this study, a final report was provided to each manufacturer participating to this study, offering them the opportunity of an independent performance appraisal in
relation to the other kits available on the market.
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As the results of the present study are exclusively related to the batches that were provided at that time by
the manufactures, the NRC established a set of verification criteria for monitoring batch-to-batch variability
based on the results obtained in this study. The verification parameters consist in the comparison of the LOD
of the ELISA to that of AGID, estimation of specificity
and CV respectively assessed from a statistically representative number of certified negative and positive samples. The batches of the kits that are approved are then
published on the NRC website so that the Official Laboratories may procure any one of them.
In view of the parameters evaluated, all the ELISAs
had an equal analytic Sp of 100%, while the best performing kits were ELISA#2 for precocity, ELISAs #1 and
#2, respectively for repeatability and reproducibility,
which were a measure of precision, and ELISA #1 and
ELISA #4 for accuracy.

Conclusions
The present study demonstrates that in general, the six
ELISAs available in Italy have similar performance characteristics except for precocity. In view of the points discussed, the EIA Italian surveillance programme adopted
this method as screening test, instead of the former
AGID based-system, to guarantee a major efficacy of the
on-going surveillance programme. The results presented
corroborate those obtained in similar studies and provide evidence to national and international regulatory
bodies, including the OIE, to reconsider the use of high
performing ELISAs for the estimation of prevalence infection and also as screening method for surveillance
purposes. The other advantages of the use of this test to
the AGID, are its standardization, automation, high
turnover of samples, cost per determination, and objective reading of sample outcomes [10].
Also, according to the different Sp and Se characterizing the kits, the authors support the parallel use of different ELISAs, already proposed in the “multitier
system” [5], which would enhance the sensitivity of the
diagnostic system and, as reported in a previous study
conducted by the authors, would require that only 1 ‰
of the examined samples be subsequently submitted to a
higher level of diagnosis in IB [5].
Further to the diagnostic quality of the ELISAs, the
technical capability of the laboratory network conducting the serological surveillance of EIA employing different tests should also undergo verification. This aspect,
together with the certification of kits for their use within
a diagnostic system, is among the institutional duties of
a NRC. In view of this, the official laboratories are periodically evaluated through the organization of ITs where
the sensitivity limits of the diagnostic system that is
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subject to verification are set through the inclusion of
weak positive and/or equivocal sera.
This double aspect, made up of high performing laboratories and methods, guarantees the efficiency of a
surveillance system.
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